Clinical trial NCT03047889: A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast
Official title: A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Advanced Breast Cancer
Lead sponsor: ChineseAMS
Sponsor class: UNKNOWN
First posted: 2017-02-09
Enrollment: 4200
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: A total of 21 hospitals were selected in this study. The investigators recruited 4200 advanced BC cases, who were first diagnosed with advanced BC from January 1st, 2012 to December 31st, 2014 from these hospitals.

Brief summary: To study the epidemiological trends and characteristics for advanced breast cancer patients, to analyze these trends and report the results

Detailed description: In this study, the investigators conducted a hospital-based retrospective clinical study, recruiting female advanced breast cancer patients from 14 tertiary hospitals at 7 classic geographic regions, to study the clinical epidemiologic characteristics of advanced breast cancer and the current standard of clinical diagnosis and treatment in order to provide references for standardized treatment therapy, and to improve the quality of life and prolong survival time.

To study the epidemiological trends and characteristics for advanced BC patients, to analyze these trends and report the results. To learn about the current treatment therapy for advanced BC patients in different areas in China.To provide references for standardized treatment therapy, to improve the quality of patients' life and to prolong the survival time for the advanced BC patients.To assess the different treatment therapies for advanced BC with consideration of economic cost-effectiveness

Eligibility criteria: Inclusion Criteria:

* diagnosed as advanced breast cancer during Jan1st,2012-Dec31st,2014
* complete with surgical pathology data, auxiliary treatment, there is a clear recurrence, transfer time, place, transfer of recurrence after treatment, and curative effect evaluation details.In any age, ethnic group cases.

Exclusion Criteria:

* no available medical record

Primary outcomes:
measure: Survival status at 3 years
timeFrame: 3 years
Secondary outcomes:
measure: PFS
timeFrame: 3 years
measure: Survival status at 5 years
timeFrame: 3 years
Other outcomes:
Locations:
city: Beijing
country: China
facility: The 307th Hospital of Military Medical Sciences
city: Chengdu
country: China
facility: Sichuan Cancer Hospital and Institute
city: Chongqing
country: China
facility: The First Affliated Hospital of Chongqing Medical University
city: Fuzhou
country: China
facility: FuZhou General Hospital of National Miltary Command
city: Guangzhou
country: China
facility: Sun Yat-Sen University Cancer Center
city: Harbin
country: China
facility: Harbin Medical University Cancer Hospital
city: Henan
country: China
facility: Henan Cancer Hospital
city: Hunan
country: China
facility: Hunan Cancer Hospital
city: Jiangsu
country: China
facility: Jiangsu Provinces hospital
city: Kunming
country: China
facility: Tumor Hospital of Yunnan Province
city: Liaoning
country: China
facility: Liaoning Cancer Hospital, Zhejiang Cancer Hospital
city: Ningxia
country: China
facility: General Hospital of NingXia Medical University
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center
city: Shenyang
country: China
facility: The First Hospital of China Medical University
city: Tianjin
country: China
facility: Tianjin Medical University Cancer Institute & Hospital
city: Wuhan
country: China
facility: Wuhan Union Hospital
city: Xi'an
country: China
facility: The First Hospital of Xi'an Jiaotong University
city: Xinjiang
country: China
facility: Xinjiang Medical University Cancer Hospital
city: Zhengzhou
country: China
facility: FuJian Provincial Cancer Hospital
Study officials:
affiliation: Chinese Academy of Medical Sciences
name: Binghe Xu
role: PRINCIPAL_INVESTIGATOR
affiliation: Chinese Academy of Medical Sciences
name: Youlin Qiao
role: PRINCIPAL_INVESTIGATOR
References:
citation: Han YQ, Yi ZB, Yu P, Wang WN, Ouyang QC, Yan M, Wang XJ, Hu XC, Jiang ZF, Huang T, Tong ZS, Wang SS, Yin YM, Li H, Yang RX, Yang HW, Teng YE, Sun T, Cai L, Li HY, Ouyang XN, He JJ, Liu XL, Yang SE, Qiao YL, Fan JH, Wang JY, Xu BH. Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from China. J Oncol. 2021 Sep 15;2021:6621722. doi: 10.1155/2021/6621722. eCollection 2021.
citation: Guo F, Yi Z, Wang W, Han Y, Yu P, Zhang S, Ouyang Q, Yan M, Wang X, Hu X, Jiang Z, Huang T, Tong Z, Wang S, Yin Y, Li H, Yang R, Yang H, Teng Y, Sun T, Cai L, Li H, Chen X, He J, Liu X, Yang S, Fan J, Qiao Y, Wang J, Xu B. Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nation-wide multicenter study. Cancer Med. 2021 Oct;10(19):6744-6761. doi: 10.1002/cam4.4215. Epub 2021 Sep 2.
citation: Wu Y, Han Y, Yu P, Ouyang Q, Yan M, Wang X, Hu X, Jiang Z, Huang T, Tong Z, Wang S, Yin Y, Li H, Yang R, Yang H, Teng Y, Sun T, Cai L, Li H, Chen X, He J, Liu X, Yang S, Qiao Y, Fan J, Wang J, Xu B. Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China. Front Oncol. 2021 Feb 11;10:599604. doi: 10.3389/fonc.2020.599604. eCollection 2020.
citation: Yi ZB, Yu P, Zhang S, Wang WN, Han YQ, Ouyang QC, Yan M, Wang XJ, Hu XC, Jiang ZF, Huang T, Tong ZS, Wang SS, Yin YM, Li H, Yang RX, Yang HW, Teng YE, Sun T, Cai L, Li HY, Chen X, He JJ, Liu XL, Yang SE, Wang JY, Fan JH, Qiao YL, Xu BH. Profile and outcome of receptor conversion in breast cancer metastases: a nation-wide multicenter epidemiological study. Int J Cancer. 2021 Feb 1;148(3):692-701. doi: 10.1002/ijc.33227. Epub 2020 Aug 19.